Twitter Facebook
Contact the Author | sample_mail@mail.com

13 Jul

The Lancet Oncolgy. Vol.16, No.4, e190-e194. April 2015 Personel View Authors: Prof. David Ashley PhD, Prof. David Thomas Ph.D, Prof. Lisa Gore MD, Prof. Rob Carter Ph.D, Prof. John R Zalcberg Ph.D, Prof.Renee Otmar Ph.D, Prof Julian Savulescu Ph.D Summary Rare cancers collectively contribute a disproportionate fraction of the total burden of cancer. The oncology community is increasingly facing small numbers of patients with each cancer subtype, requiring cooperation and collaboration to complete multicentre trials that advance knowledge and patient care……

Read more

13 Jun

The Lancet. Vol.385 April 4th 2015. Pgs 1279-1280 Medicines in Europe could spin out of control unless authorities act urgently to create a central base of supply disruptions, adopt preventive measures, and draw up contingency plans to ensure patients’ lives are not endangered, says health professionals. A report published by the European Association of Hospital Pharmacists (EAHP)  last November showed 86% of 607 practitioners in 36 Europeans countries had sourcing problems, and 66% said this problem arose on a daily…..

Read more

13 Jun

Osteosarcoma: mixed efficacy of sorafenib and everolimus treatment Consult the Pubmed abstract. Lancet Oncol.;S1470-2045(14)71136-2; December 2014 To read more on Osteosarcoma

Read more

12 May

This is very encouraging news! Author Chris Lancashire in her autobiography called ‘Beyond Courage” is highlighting this ‘Forgotten Cancers Project” launched on the 26th August 2011. In this project 15 ‘Target Cancers ‘ had been selected for specific reasons such as poor survival rate and or limited understanding of their causes. One of these Target Cancers is bone cancer. In her book, the author is raising community and global awareness of this rarest bone cancer, Chondroblastic Osteosarcoma. Read below :…..

Read more